Skip to main content
Erschienen in: Current Breast Cancer Reports 3/2018

24.07.2018 | Global Breast Cancer (BO Anderson and C Duggan, Section Editors)

Breast Cancer Diagnosis and Treatment in Low- and Mid-Resource Settings: the Role of Resource-Stratified Clinical Practice Guidelines

verfasst von: Nagi S. El Saghir, Paul A. El Tomb, Robert W. Carlson

Erschienen in: Current Breast Cancer Reports | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

One of the most important recent advances in the management of cancer patients have become the development of guidelines. Guidelines are usually evidence-based or international consensus guidelines. Those guidelines may not be applicable worldwide, especially where resources are limited. This prompted initiatives for the development of resource-stratified guidelines so that health care providers and authorities can do the best they can with the resources they have, while working on improving their resources. We will describe the process of development of those guidelines and briefly review recommendations for awareness, screening, diagnosis, and treatment of breast cancer, focusing on countries and special populations with limited resources.

Recent Findings

The World Health Organization (WHO) described three resource scenarios (low-resource, middle-resource, and high-resource scenarios) in order to facilitate the establishment of national cancer control plans. The Breast Health Global Initiative (BHGI), as an initiative group with goals to improve the care of patients with breast cancer in low- and mid-resource settings, identified four levels of resource availability (basic, limited, enhanced, and maximal) with comprehensive sets of recommendations for each. BHGI published resource-stratified breast cancer guidelines starting in 2006, and later on updated them and focused on implementation and health systems. The National Comprehensive Cancer Network (NCCN) initiated a program, building upon the BHGI experience to resource stratify cancer treatment guidelines across multiple cancer types and published NCCN Framework for resource stratification in breast cancer in 2016. Subsequently, the NCCN has published multiple additional resource stratification frameworks that use slightly different definitions of resource level than use by the BHGI. The American Society of Clinical Oncology (ASCO) has also assembled a Guidelines Advisory Group for Resource Stratification for different cancers, and published its first comprehensive resource-stratified guidelines for cancer of the cervix.

Summary

International efforts to improve management and reduce disparities in the outcome of breast cancer patients’ worldwide focus on recommendations for better allocation of available resources in different countries. The WHO, BHGI, NCCN, ASCO, and other international initiatives issued various resource-stratified guidelines (RSG) based on levels of resources in different countries. We shed the light on the development of these guidelines and discuss awareness, prevention of advanced disease at presentation, and management. Future research is needed to update and improve dissemination and implementation of RSG, as well as building infrastructure, reforming of health systems, and better allocating resources.
Literatur
1.
Zurück zum Zitat International Agency for Research on Cancer. World Health Organization, gco.iarc.fr/today/home, Accessed March 29, 2018. International Agency for Research on Cancer. World Health Organization, gco.​iarc.​fr/today/home, Accessed March 29, 2018.
4.
Zurück zum Zitat Anderson BO, Braun S, Carlson RW, et al. Overview of breast health care guidelines for countries with limited resources. Breast J. 2003;2:S42–5035.CrossRef Anderson BO, Braun S, Carlson RW, et al. Overview of breast health care guidelines for countries with limited resources. Breast J. 2003;2:S42–5035.CrossRef
5.
Zurück zum Zitat Anderson BO, Yip C, Ramsey SD, et al. Breast cancer in limited-resource countries: health care systems and public policy. Breast J. 2006;12(s1):S54–69.CrossRefPubMed Anderson BO, Yip C, Ramsey SD, et al. Breast cancer in limited-resource countries: health care systems and public policy. Breast J. 2006;12(s1):S54–69.CrossRefPubMed
6.
Zurück zum Zitat Anderson BO, Cazap E, El Saghir NS, et al. Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010. Lancet Oncol. 2011;12:387–98.CrossRefPubMed Anderson BO, Cazap E, El Saghir NS, et al. Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010. Lancet Oncol. 2011;12:387–98.CrossRefPubMed
9.
Zurück zum Zitat •• Carlson RW, Scavone JL, Koh WJ, et al. NCCN Framework for resource stratification: a framework for providing and improving global quality oncology care. J Natl Compr Cancer Netw. 2016;14:961–9. This study shows the need and necessity of having RSGs to treat better cancer patients in LMICs, and offers the most updated RSGs made in 2016 by the NCCN Framework. CrossRef •• Carlson RW, Scavone JL, Koh WJ, et al. NCCN Framework for resource stratification: a framework for providing and improving global quality oncology care. J Natl Compr Cancer Netw. 2016;14:961–9. This study shows the need and necessity of having RSGs to treat better cancer patients in LMICs, and offers the most updated RSGs made in 2016 by the NCCN Framework. CrossRef
10.
Zurück zum Zitat Eniu A, Carlson RW, El Saghir NS, Bines J, Bese NS, Vorobiof D, et al. Guideline implementation for breast healthcare in low- and middle-income countries: treatment resource allocation. Cancer. 2008 Oct 15;113(8 Suppl):2269–81. https://doi.org/10.1002/cncr.23843. Eniu A, Carlson RW, El Saghir NS, Bines J, Bese NS, Vorobiof D, et al. Guideline implementation for breast healthcare in low- and middle-income countries: treatment resource allocation. Cancer. 2008 Oct 15;113(8 Suppl):2269–81. https://​doi.​org/​10.​1002/​cncr.​23843.
17.
Zurück zum Zitat Schwam ZG, Sosa JA, Roman S, et al. Receipt of care discordant with practice guidelines is associated with compromised overall survival in nasopharyngeal carcinoma. Clin Oncol (R Coll Radiol). 2016;28:1–8.CrossRef Schwam ZG, Sosa JA, Roman S, et al. Receipt of care discordant with practice guidelines is associated with compromised overall survival in nasopharyngeal carcinoma. Clin Oncol (R Coll Radiol). 2016;28:1–8.CrossRef
18.
Zurück zum Zitat Yip CH, Smith RA, Anderson BO, et al. Guideline implementation for breast healthcare in low- and middle-income countries: early detection resource allocation. Cancer. 2008;113(8 Suppl):2244–56.CrossRefPubMed Yip CH, Smith RA, Anderson BO, et al. Guideline implementation for breast healthcare in low- and middle-income countries: early detection resource allocation. Cancer. 2008;113(8 Suppl):2244–56.CrossRefPubMed
19.
20.
Zurück zum Zitat El Saghir NS, Farhat RA, Charara RN, et al. Enhancing cancer care in areas of limited resources: our next steps. Future Oncol. 2014;10:1953–65.CrossRefPubMed El Saghir NS, Farhat RA, Charara RN, et al. Enhancing cancer care in areas of limited resources: our next steps. Future Oncol. 2014;10:1953–65.CrossRefPubMed
22.
Zurück zum Zitat Shyyan R, Sener SF, Anderson BO, Fernández Garrote LM, Hortobágyi GN, Ibarra JA Jr, et al. Guideline implementation for breast healthcare in low- and middle-income countries: diagnosis resource allocation. Cancer. 2008;113(8 Suppl):2257–68.CrossRefPubMed Shyyan R, Sener SF, Anderson BO, Fernández Garrote LM, Hortobágyi GN, Ibarra JA Jr, et al. Guideline implementation for breast healthcare in low- and middle-income countries: diagnosis resource allocation. Cancer. 2008;113(8 Suppl):2257–68.CrossRefPubMed
24.
Zurück zum Zitat Rugo HS, Barve A, Waller CF, et al. Heritage: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin. ASCO Annual Meeting; Chicago, IL; Jun 3–7, 2016. LBA503. Rugo HS, Barve A, Waller CF, et al. Heritage: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin. ASCO Annual Meeting; Chicago, IL; Jun 3–7, 2016. LBA503.
26.
Zurück zum Zitat Yip CH, Cazap E, Anderson BO, et al. Breast cancer management in middle-resource countries: consensus statement from the Breast Health Global Initiative. Breast, April 2011; 20 (TBD). Yip CH, Cazap E, Anderson BO, et al. Breast cancer management in middle-resource countries: consensus statement from the Breast Health Global Initiative. Breast, April 2011; 20 (TBD).
27.
Zurück zum Zitat Sullivan R, Alatise OI, Anderson BO, Audisio R, Autier P, Aggarwal A, et al. Global cancer surgery: delivering safe, affordable, and timely cancer surgery. Lancet Oncol. 2015;16:1193–224.CrossRefPubMed Sullivan R, Alatise OI, Anderson BO, Audisio R, Autier P, Aggarwal A, et al. Global cancer surgery: delivering safe, affordable, and timely cancer surgery. Lancet Oncol. 2015;16:1193–224.CrossRefPubMed
29.
Zurück zum Zitat Atun R, Jaffray DA, Barton MB, Bray F, Baumann M, Vikram B, et al. Expanding global access to radiotherapy. Lancet Oncol. 2015;16:1153–86.CrossRefPubMed Atun R, Jaffray DA, Barton MB, Bray F, Baumann M, Vikram B, et al. Expanding global access to radiotherapy. Lancet Oncol. 2015;16:1153–86.CrossRefPubMed
31.
Zurück zum Zitat Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013;14(8):741–8.CrossRefPubMed Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013;14(8):741–8.CrossRefPubMed
32.
Zurück zum Zitat Joensuu H, Fraser J, Wildiers H, et al. A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer. The Synergism Or Long Duration (SOLD) trial. Presented at: 2017 San Antonio Breast Cancer Symposium; December 5–9, 2017; San Antonio, TX. Abstract GS3–04. Joensuu H, Fraser J, Wildiers H, et al. A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer. The Synergism Or Long Duration (SOLD) trial. Presented at: 2017 San Antonio Breast Cancer Symposium; December 5–9, 2017; San Antonio, TX. Abstract GS3–04.
33.
Zurück zum Zitat Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009;27:5685–92.CrossRefPubMed Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009;27:5685–92.CrossRefPubMed
34.
Zurück zum Zitat •• El Saghir NS, Kreidieh FY, El-Baba S, Anderson BO. Management of locally advanced and metastatic breast cancer: guidelines, infrastructures and low resource settings. Breast Cancer Manage. 2016;5(2):69–77. This article tackles a specific group of patients in LMICs, which is the locally advanced/metastatic breast cancer group. It is important to know that resources needed in the management of cancer at this advanced stage requires proper infrastructure that is not always present in low-resource countries. In this article, disparities in the breast cancer outcomes and requirements for optimal management are reviewed, including infrastructure needs for optimal surgery, radiation treatment, and systemic therapy. In addition, the article mentions controversies related to drug pricing and availability and process and delays in registration of new drugs as well as resource stratification. CrossRef •• El Saghir NS, Kreidieh FY, El-Baba S, Anderson BO. Management of locally advanced and metastatic breast cancer: guidelines, infrastructures and low resource settings. Breast Cancer Manage. 2016;5(2):69–77. This article tackles a specific group of patients in LMICs, which is the locally advanced/metastatic breast cancer group. It is important to know that resources needed in the management of cancer at this advanced stage requires proper infrastructure that is not always present in low-resource countries. In this article, disparities in the breast cancer outcomes and requirements for optimal management are reviewed, including infrastructure needs for optimal surgery, radiation treatment, and systemic therapy. In addition, the article mentions controversies related to drug pricing and availability and process and delays in registration of new drugs as well as resource stratification. CrossRef
35.
Zurück zum Zitat El Saghir NS, Adebamowo CA, Anderson BO, et al. Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative. Breast. 2011;20:S3–S11.CrossRefPubMed El Saghir NS, Adebamowo CA, Anderson BO, et al. Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative. Breast. 2011;20:S3–S11.CrossRefPubMed
36.
Zurück zum Zitat Ganz PA, Yip CH, Gralow JR, Distelhorst SR, Albain KS, Andersen BL, et al. Supportive care after curative treatment for breast cancer (survivorship care): resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. Breast. 2013;22:606–15.CrossRefPubMed Ganz PA, Yip CH, Gralow JR, Distelhorst SR, Albain KS, Andersen BL, et al. Supportive care after curative treatment for breast cancer (survivorship care): resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. Breast. 2013;22:606–15.CrossRefPubMed
38.
Zurück zum Zitat Cazap E, Distelhorst SR, Anderson BO. Implementation science and breast cancer control: a Breast Health Global Initiative (BHGI) perspective from the 2010 Global Summit. Breast. 2011;20(suppl 2):S1–2.CrossRefPubMed Cazap E, Distelhorst SR, Anderson BO. Implementation science and breast cancer control: a Breast Health Global Initiative (BHGI) perspective from the 2010 Global Summit. Breast. 2011;20(suppl 2):S1–2.CrossRefPubMed
40.
Zurück zum Zitat El Saghir NS, Carlson RW, Khoury KE, Fallowfield L. Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of cancer patients worldwide. Am Soc Clin Oncol Educ Book. 2014;2014:e461–6.CrossRef El Saghir NS, Carlson RW, Khoury KE, Fallowfield L. Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of cancer patients worldwide. Am Soc Clin Oncol Educ Book. 2014;2014:e461–6.CrossRef
41.
Zurück zum Zitat El Saghir N, El Asmar N, Hajj C, et al. Survey of utilization of multidisciplinary management tumor boards in Arab countries. Breast. 2011;20(Suppl 2):S70–4.CrossRefPubMed El Saghir N, El Asmar N, Hajj C, et al. Survey of utilization of multidisciplinary management tumor boards in Arab countries. Breast. 2011;20(Suppl 2):S70–4.CrossRefPubMed
42.
Zurück zum Zitat El Saghir NS, Charara RN, Kreidieh FY, et al. Global practice and efficiency of multidisciplinary tumor boards: results of an American Society of Clinical Oncology international survey. J Global Oncol. 2015;1:57–64.CrossRef El Saghir NS, Charara RN, Kreidieh FY, et al. Global practice and efficiency of multidisciplinary tumor boards: results of an American Society of Clinical Oncology international survey. J Global Oncol. 2015;1:57–64.CrossRef
50.
Zurück zum Zitat •• El Saghir NS, Perez de Celis ES, Fares JE, Sullivan R. Cancer care for refugees and displaced populations: Middle East conflicts and global natural disasters. 2018 American Society of Clinical Oncology ASCO Educational Book: http://ascopubs.org/doi/abs/10.1200/EDBK_201365. This article brings a new dimension to the subject of underprivileged cancer patients, which are refugees and displaced populations. It incites the WHO, UN, BHGI, ASCO, NCCN, and others to think about solutions for cancer patients in these communities. •• El Saghir NS, Perez de Celis ES, Fares JE, Sullivan R. Cancer care for refugees and displaced populations: Middle East conflicts and global natural disasters. 2018 American Society of Clinical Oncology ASCO Educational Book: http://​ascopubs.​org/​doi/​abs/​10.​1200/​EDBK_​201365. This article brings a new dimension to the subject of underprivileged cancer patients, which are refugees and displaced populations. It incites the WHO, UN, BHGI, ASCO, NCCN, and others to think about solutions for cancer patients in these communities.
Metadaten
Titel
Breast Cancer Diagnosis and Treatment in Low- and Mid-Resource Settings: the Role of Resource-Stratified Clinical Practice Guidelines
verfasst von
Nagi S. El Saghir
Paul A. El Tomb
Robert W. Carlson
Publikationsdatum
24.07.2018
Verlag
Springer US
Erschienen in
Current Breast Cancer Reports / Ausgabe 3/2018
Print ISSN: 1943-4588
Elektronische ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-018-0287-6

Weitere Artikel der Ausgabe 3/2018

Current Breast Cancer Reports 3/2018 Zur Ausgabe

Global Breast Cancer (BO Anderson and C Duggan, Section Editors)

Factors Contributing to Late-Stage Breast Cancer Presentation in sub-Saharan Africa

Global Breast Cancer (BO Anderson and C Duggan, Section Editors)

Breast Cancer Disparities Among Women in Underserved Communities in the USA

Risk and Prevention (ME Wood, Section Editor)

Risk and Prevention for Highly Penetrant Genes

Global Breast Cancer (BO Anderson and C Duggan, Section Editors)

Breast Cancer Disparities Among Women in Low- and Middle-Income Countries

Global Breast Cancer (BO Anderson and C Duggan, Section Editors)

Access to Affordable Breast Cancer Care in Eastern Europe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.